- Long-term Efficacy and Predictors of Response to Infliximab in Korean Patients with Crohn's Disease
-
Lee KM
- KMID: 1501644
- Korean J Gastroenterol.
- 2013 May;61(5):241-242.
- doi: 10.4166/kjg.2013.61.5.241
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Cross-Regulation of Innate and Adaptive Immunity: A New Perspective for the Pathogenesis of Inflammatory Bowel Disease
-
Oh DY, Koh SJ
- KMID: 2155636
- Gut Liver.
- 2015 May;9(3):263-264.
- doi: 10.5009/gnl15123
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)
-
Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, Shim YR
- KMID: 1717990
- Korean J Intern Med.
- 2007 Mar;22(1):24-27.
- doi: 10.3904/kjim.2007.22.1.24
Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Octreotide on Small Bowel Obstructions in Rats
-
Cho JH, Kang HG, Kim SH, Lee HS, Lee KR, Kang HY
- KMID: 772558
- Korean J Gastroenterol.
- 2003 Oct;42(4):283-288.
BACKGROUNDS/AIMS: Gastrointestinal decompression by nasogastric or intestinal tubes developed in 1930s has been the only treatment modality for inoperable intestinal obstruction. We hypothesized that the octreotide, a potent inhibitor of... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of TIM-3, Human beta-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy
-
Kim MJ, Lee WY, Choe YH
- KMID: 2155645
- Gut Liver.
- 2015 May;9(3):370-380.
- doi: 10.5009/gnl13408
BACKGROUND/AIMS: This study investigated the expression of T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), human beta-defensin (HBD)-2, forkhead box protein 3 (FOXP3), and the frequency of CD4+ CD25+ FOXP3+... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
-
Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)
- KMID: 2411966
- Gut Liver.
- 2016 May;10(3):391-398.
- doi: 10.5009/gnl15126
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of New Prokinetic Agent Benachio Q Solution(R) in Patients with Postprandial Distress Syndrome Subtype in Functional Dyspepsia: A Single-center, Randomized, Double-blind, Placebo-controlled Pilot Study
-
Shim YK, Lee JY, Kim N, Park YH, Yoon H, Shin CM, Park YS, Lee DH
- KMID: 2373307
- Korean J Gastroenterol.
- 2015 Jul;66(1):17-26.
- doi: 10.4166/kjg.2015.66.1.17
BACKGROUND/AIMS: Functional dyspepsia (FD) is a gastrointestinal disorder in which the patient suffers from chronic abdominal symptoms despite the absence of organic disease. Benachio Q solution (soln.)(R) is a new... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Mosapride on Quality of Life in Functional Dyspepsia
-
Cho YK, Choi MG, Kim SH, Lee IS, Kim SW, Chung IS, Lee SY, Choi SC, Seol SY
- KMID: 772622
- Korean J Gastroenterol.
- 2004 Mar;43(3):160-167.
BACKGROUND/AIMS: It is unknown whether the prokinetics improve the quality of life in patients with functional dyspepsia. Thus, we evaluate the effect of the mosapride, selective 5-HT4 agonist, on... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Infliximab in the Treatment of Refractory Inflammatory Bowel Disease with Complication
-
Lee KM, Kim JS, Shin DH, Cheong JY, Yoo BM, Kim JK, Lee KJ, Hahm KB, Kim JH, Cho SW
- KMID: 772694
- Korean J Gastroenterol.
- 2004 Nov;44(5):259-266.
BACKGROUND/AIMS: Many studies on infliximab have confirmed its efficacy in the remission induction and even maintenance in refractory and fistulizing Crohn's disease. We report the treatment efficacy of infliximab... -
- CITED
-
- Close
- SHARE
-
- Close
